Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + cyclophosphamide + pegylated liposomal doxorubicin
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen that includes three anticancer drugs: 5-fluorouracil (5-FU), cyclophosphamide, and pegylated liposomal doxorubicin. This combination is a variation of the standard FAC (5-fluorouracil, Adriamycin/doxorubicin, cyclophosphamide) regimen, where conventional doxorubicin is replaced with pegylated liposomal doxorubicin. **Mechanism of action:** - 5-Fluorouracil: An antimetabolite that stops cells from making and repairing DNA, causing cell death during division - Cyclophosphamide: An alkylating agent that stops cancer cells from reproducing - Pegylated liposomal doxorubicin: A formulation of doxorubicin encapsulated in liposomes coated with polyethylene glycol (PEG). This formulation allows for preferential uptake by tumor tissue while reducing exposure to normal tissues, particularly the heart
- Other names
- FAC with pegylated liposomal doxorubicin
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on 5-fluorouracil + cyclophosphamide + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + pegylated liposomal doxorubicin.